Որոնման արդյունքները - Marice Alcantara
- Ցուցադրվում են 1 - 6 արդյունքները 6
-
1
Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3 Jeremy Hall, Zhuoran Zhang, S. Bhattacharya, Dongfang Wang, Marice Alcantara, Liang Yong, Piotr Swiderski, Stephen J. Forman, Larry W. Kwak, Nagarajan Vaidehi, Marcin Kortylewski
Հրապարակվել է 2024Artigo -
2
Myeloid cell–targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell–mediated immunity Dayson Moreira, Sagus Sampath, Haejung Won, Seok Voon White, Yu‐Lin Su, Marice Alcantara, Chongkai Wang, Peter P. Lee, Ellie Maghami, Erminia Massarelli, Marcin Kortylewski
Հրապարակվել է 2020Artigo -
3
Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma Alex Chehrazi‐Raffle, Luís Meza, Marice Alcantara, Nazlı Dizman, Paulo Gustavo Bergerot, Nicholas Salgia, Joann Hsu, Nora Ruel, Sabrina Salgia, Jasnoor Malhotra, Ewa Karczewska, Marcin Kortylewski, Sumanta K. Pal
Հրապարակվել է 2021Artigo -
4
Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy Marice Alcantara, Wilson S. Tang, Dongfang Wang, Damian Kaniowski, Elaine Kang, Nazlı Dizman, Alex Chehrazi‐Raffle, Luís Meza, Zeynep Büşra Zengin, Jérémy Hall, Joann Hsu, Colt A. Egelston, Dayson Moreira, Alan Horsager, Sumanta K. Pal, Marcin Kortylewski
Հրապարակվել է 2024Artigo -
5
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial Nazlı Dizman, Luís Meza, Paulo Gustavo Bergerot, Marice Alcantara, Tanya B. Dorff, Yung Lyou, Paul Frankel, Yujie Cui, Valerie Mira, Marian Llamas, Joann Hsu, Zeynep Büşra Zengin, Nicholas Salgia, Sabrina Salgia, Jasnoor Malhotra, Neal Shiv Chawla, Alex Chehrazi‐Raffle, Ramya Muddasani, John D. Gillece, Lauren Reining, J.M. Trent, Motomichi Takahashi, Kentaro Oka, Seiya Higashi, Marcin Kortylewski, Sarah K. Highlander, Sumanta K. Pal
Հրապարակվել է 2022Artigo -
6
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial Hedyeh Ebrahimi, Nazlı Dizman, Luís Meza, Jasnoor Malhotra, Xiaochen Li, Tanya B. Dorff, Paul Frankel, Marian Llamas-Quitiquit, Joann Hsu, Zeynep Büşra Zengin, Marice Alcantara, Daniela V. Castro, Benjamin Mercier, Neal Shiv Chawla, Alex Chehrazi‐Raffle, Regina Barragán-Carrillo, Salvador Jaime‐Casas, Ameish Govindarajan, John D. Gillece, Jeffrey M. Trent, Peter P. Lee, Thomas P. Parks, Motomichi Takahashi, Atsushi Hayashi, Marcin Kortylewski, J. Gregory Caporaso, Keehoon Lee, Abhishek Tripathi, Sumanta K. Pal
Հրապարակվել է 2024Artigo
Որոնման գործիքներ:
Առնչվող խորագիր
Internal medicine
Medicine
Cancer
Immunotherapy
Cancer research
Nivolumab
Oncology
Renal cell carcinoma
Clinical endpoint
Gastroenterology
Immune system
Immunology
Ipilimumab
Myeloid
Randomized controlled trial
Tumor microenvironment
Axitinib
Bladder cancer
Breast cancer
CD8
Cabozantinib
Chemistry
Computer science
Confidence interval
Degradation (telecommunications)
Hazard ratio
Head and neck cancer
Head and neck squamous-cell carcinoma
Immune checkpoint
Radiation therapy